Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

400 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeted Delivery of an Anti-inflammatory PDE4 Inhibitor to Immune Cells via an Antibody-drug Conjugate.
Yu S, Pearson AD, Lim RK, Rodgers DT, Li S, Parker HB, Weglarz M, Hampton EN, Bollong MJ, Shen J, Zambaldo C, Wang D, Woods AK, Wright TM, Schultz PG, Kazane SA, Young TS, Tremblay MS. Yu S, et al. Among authors: pearson ad. Mol Ther. 2016 Dec;24(12):2078-2089. doi: 10.1038/mt.2016.175. Epub 2016 Oct 12. Mol Ther. 2016. PMID: 27731313 Free PMC article.
A vimentin binding small molecule leads to mitotic disruption in mesenchymal cancers.
Bollong MJ, Pietilä M, Pearson AD, Sarkar TR, Ahmad I, Soundararajan R, Lyssiotis CA, Mani SA, Schultz PG, Lairson LL. Bollong MJ, et al. Among authors: pearson ad. Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9903-E9912. doi: 10.1073/pnas.1716009114. Epub 2017 Oct 30. Proc Natl Acad Sci U S A. 2017. PMID: 29087350 Free PMC article.
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer.
Pearson AD, DuBois SG, Macy ME, de Rojas T, Donoghue M, Weiner S, Knoderer H, Bernardi R, Buenger V, Canaud G, Cantley L, Chung J, Fox E, Friend J, Glade-Bender J, Gorbatchevsky I, Gore L, Gupta A, Hawkins DS, Juric D, Lang LA, Leach D, Liaw D, Lesa G, Ligas F, Lindberg G, Lindberg W, Ludwinski D, Marshall L, Mazar A, McDonough J, Nysom K, Ours C, Pappo A, Parsons DW, Rosenfeld A, Scobie N, Smith M, Taylor D, Weigel B, Weinstein A, Karres D, Vassal G. Pearson AD, et al. Eur J Cancer. 2024 Aug;207:114145. doi: 10.1016/j.ejca.2024.114145. Epub 2024 Jun 8. Eur J Cancer. 2024. PMID: 38936103 Free article. Review.
Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer.
Bautista F, Verdú-Amorós J, Geoerger B, Rubio-San-Simón A, Paoletti X, Zwaan CM, Casanova M, Marshall LV, Carceller F, Doz F, Lecinse C, Vassal G, Pearson ADJ, Kearns P, Moreno L; Innovative Therapies For Children With Cancer Consortium. Bautista F, et al. Among authors: pearson adj. J Clin Oncol. 2024 Jul 20;42(21):2516-2526. doi: 10.1200/JCO.23.01237. Epub 2024 May 14. J Clin Oncol. 2024. PMID: 38743911
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.
Moreno L, Weston R, Owens C, Valteau-Couanet D, Gambart M, Castel V, Zwaan CM, Nysom K, Gerber N, Castellano A, Laureys G, Ladenstein R, Rössler J, Makin G, Murphy D, Morland B, Vaidya S, Thebaud E, van Eijkelenburg N, Tweddle DA, Barone G, Tandonnet J, Corradini N, Chastagner P, Paillard C, Bautista FJ, Gallego Melcon S, De Wilde B, Marshall L, Gray J, Burchill SA, Schleiermacher G, Chesler L, Peet A, Leach MO, McHugh K, Hayes R, Jerome N, Caron H, Laidler J, Fenwick N, Holt G, Moroz V, Kearns P, Gates S, Pearson ADJ, Wheatley K; Innovative Therapies for Children with Cancer (ITCC) and European Association for Neuroblastoma Research (SIOPEN). Moreno L, et al. Among authors: pearson adj. J Clin Oncol. 2024 Apr 1;42(10):1135-1145. doi: 10.1200/JCO.23.00458. Epub 2024 Jan 8. J Clin Oncol. 2024. PMID: 38190578 Free article. Clinical Trial.
Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed.
Rossig C, Pearson AD, Vassal G, Scobie N, Bird N, Blanc P, Vormoor HJ, Calkoen FG, Locatelli F, Del Bufalo F, Rives S, Jacoby E, Balduzzi A, Bourquin JP, Baruchel A. Rossig C, et al. Among authors: pearson ad. J Clin Oncol. 2024 Jan 20;42(3):253-257. doi: 10.1200/JCO.23.01314. Epub 2023 Nov 27. J Clin Oncol. 2024. PMID: 38011605 No abstract available.
400 results